The safety database includes 941 patients from clinical trials and approximately 23,000 patients in the Expanded Access Program.
Table 1 includes drug-related adverse events with an incidence of 5% for the 216 patients who received either 250 mg or 500 mg of Gefitinib monotherapy for treatment of NSCLC. The most common adverse events reported at the recommended 250 mg daily dose were diarrhea, rash, acne, dry skin, nausea, and vomiting. The 500 mg dose showed a higher rate for most of these adverse events.
Table 2 provides drug-related adverse events with an incidence of 5% by common toxicity (CTC) grade for the patients who received the 250 mg/day dose of Gefitinib monotherapy for treatment of NSCLC. Only 2% of patients stopped therapy due to an adverse drug reaction (ADR). The onset of these ADRs occurred within the first month of therapy. (See Table 1 and 2.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Other adverse events reported at an incidence of <5% in patients who received either 250 mg or 500 mg as monotherapy for treatment of NSCLC (along with their frequency at the 250 mg recommended dose) include the following: peripheral edema (2%), amblyopia (2%), dyspnea (2%), conjunctivitis (1%), vesiculobullous rash (1%) and mouth ulceration (1%).
Interstitial Lung Disease: Cases of interstitial lung disease (ILD) have been observed in patients receiving QUALITINIB at an overall incidence of about 1% approximately 1/3 of the cases have been fatal. The reported incidence of ILD was about 2% in the Japanese post-marketing experience, about 0.3% in approximately 23,000 patients treated with Gefitinib in a US expanded access program and about 1% in the studies of first-line use in NSCLC (but with similar rates in both treatment and placebo groups). Reports have described the adverse event as interstitial pneumonia, pneumonitis and alveolitis. Patients often present with the acute onset of dyspnea, sometimes associated with cough or low-grade fever, often becoming severe within a short time and requiring hospitalization. ILD has occurred in patients who have received prior radiation therapy (31% of reported cases), prior chemotherapy (57% of reported patients), and no previous therapy (12% of reported cases). Patients with concurrent idiopathic pulmonary fibrosis whose condition worsens while receiving Gefitinib have been observed to have an increased mortality compared to those without concurrent idiopathic pulmonary fibrosis. In the event of acute onset or worsening of pulmonary symptoms (dyspnea, cough, fever), Gefitinib therapy should be interrupted and a prompt investigation of these symptoms should occur.
Others: In patients receiving Gefitinib therapy, there were reports of eye pain and corneal erosion/ulcer, sometimes in association with aberrant eyelash growth. Hemorrhage, such as epistaxis and hematuria have been reported in patients receiving Gefitinib. There were also rare reports of pancreatitis and very rare reports of corneal membrane sloughing, ocular ischemia/hemorrhage, toxic epidermal necrolysis, erythema multiforme, and allergic reactions, including angioedema and urticaria.
International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on Gefitinib therapy. Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR. Data from non-clinical (in vitro and in vivo) studies indicate that Gefitinib has the potential to inhibit the cardiac action potential repolarization process (eg, QT interval). The clinical relevance of these findings is unknown.